Medicilon Supports Partner Luye Pharma's LY09607 Clinical Trial Approval

Shanghai, China – [Date] – Medicilon is proud to have supported Luye Pharmaceutical Co., Ltd. ("Luye Pharma") in securing clinical trial approval for LY09607, a new drug aimed at improving post-operative pain management.

LY09607: A Breakthrough in Pain Relief

LY09607, developed by Luye Pharma, has recently been approved for clinical trials in China. This drug addresses a significant gap in post-operative pain management, an issue affecting millions globally, with over 313 million surgeries performed annually. Approximately 75% of patients experience moderate to severe pain, often managed with opioids. However, opioid use is limited by addiction risks and side effects, highlighting the need for alternatives. LY09607 offers a promising new option for long-term pain relief, complementing the success of Luye Pharma’s previous pain management product, Mimixin®, approved in June 2024.

Medicilon’s Role in Drug Development

Medicilon has played a key role in the development of LY09607 by providing comprehensive preclinical research services, including a variety of pain evaluation models. These models - such as the hot plate, tail-flick, and Von Frey tests, are essential for testing the efficacy and safety of pain relief drugs. Medicilon’s rigorous validation of these models supports the development of safer, more effective treatments for pain.

Congratulations to Luye Pharma

Medicilon extends its congratulations to Luye Pharma on this significant milestone. We look forward to the continued success of LY09607 in clinical trials and remain committed to supporting global drug development through our cutting-edge preclinical services.

About Luye Pharma

Luye Pharma Group is a global pharmaceutical company dedicated to the research, development, and commercialization of innovative drugs. With a robust pipeline of over 30 drug candidates and expertise in advanced drug delivery technologies, Luye Pharma operates internationally with R&D centers in China, the U.S., and Europe. The company focuses on oncology, CNS, cardiovascular, and metabolic diseases, and has a growing presence in cell and gene therapies.

About Medicilon

Founded in 2004, Medicilon is a leading provider of preclinical drug research services. Based in Shanghai, Medicilon supports pharmaceutical companies and research institutions worldwide with comprehensive services that span the entire drug development process. With over 2,000 clients and 490 IND-approved drugs, Medicilon is at the forefront of advancing global pharmaceutical innovation.